Overview

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

Status:
Not yet recruiting
Trial end date:
2025-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
IQVIA RDS (Shanghai) Co., Ltd.